{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:46:40Z","timestamp":1770482800055,"version":"3.49.0"},"reference-count":99,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1097\/gme.0b013e3181e324a6","type":"journal-article","created":{"date-parts":[[2010,7,27]],"date-time":"2010-07-27T01:26:19Z","timestamp":1280193979000},"page":"109-118","source":"Crossref","is-referenced-by-count":28,"title":["Preventing osteoporosis in symptomatic postmenopausal women"],"prefix":"10.1097","volume":"18","author":[{"given":"J. Christopher","family":"Gallagher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey P.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-22-20210227","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1477-7525-3-47","article-title":"Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review.","volume":"3","author":"Utian","year":"2005","journal-title":"Health Qual Life Outcomes"},{"key":"R2-22-20210227","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0378-5122(03)00181-6","article-title":"Effects of 5 years of hormonal replacement therapy on menopausal symptoms and blood pressure-a randomised controlled study.","volume":"46","author":"Vestergaard","year":"2003","journal-title":"Maturitas"},{"key":"R3-22-20210227","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/nur.4770080308","article-title":"The prevalence of hot flash and associated variables among perimenopausal women.","volume":"8","author":"Feldman","year":"1985","journal-title":"Res Nurs Health"},{"key":"R4-22-20210227","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00042192-200205000-00003","article-title":"A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century.","volume":"9","author":"Rodstrom","year":"2002","journal-title":"Menopause"},{"key":"R5-22-20210227","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/archinte.166.12.1262","article-title":"Severe hot flashes are associated with chronic insomnia.","volume":"166","author":"Ohayon","year":"2006","journal-title":"Arch Intern Med"},{"key":"R6-22-20210227","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1001\/jama.1981.03310420031025","article-title":"Association of waking episodes with menopausal hot flushes.","volume":"245","author":"Erlik","year":"1981","journal-title":"JAMA"},{"key":"R7-22-20210227","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000419425","article-title":"The neuroendocrine aspects of menopausal hot flashes.","volume":"6","author":"Lu","year":"1991","journal-title":"Prog Basic Clin Pharmacol"},{"key":"R8-22-20210227","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s11606-008-0655-4","article-title":"Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis.","volume":"23","author":"Politi","year":"2008","journal-title":"J Gen Intern Med"},{"key":"R9-22-20210227","doi-asserted-by":"crossref","first-page":"605","DOI":"10.47102\/annals-acadmedsg.V32N5p605","article-title":"Use of hormone replacement therapy in the asymptomatic postmenopausal woman: what is the current evidence?","volume":"32","author":"Loh","year":"2003","journal-title":"Ann Acad Med Singapore"},{"key":"R10-22-20210227","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s001920170074","article-title":"Urogenital prolapse and atrophy at menopause: a prevalence study.","volume":"12","author":"Versi","year":"2001","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"R11-22-20210227","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/PL00004023","article-title":"Urogenital symptoms and resulting discomfort in non-institutionalized Dutch women aged 50-75 years.","volume":"11","author":"van Geelen","year":"2000","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"R12-22-20210227","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.0001-6349.2005.00645.x","article-title":"A study on urogenital complaints of postmenopausal women aged 50 and over.","volume":"84","author":"Oskay","year":"2005","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R13-22-20210227","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.maturitas.2005.03.012","article-title":"Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens\/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study.","volume":"52","author":"Haines","year":"2005","journal-title":"Maturitas"},{"key":"R14-22-20210227","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1172\/JCI28550","article-title":"Estrogen deficiency and bone loss: an inflammatory tale.","volume":"116","author":"Weitzmann","year":"2006","journal-title":"J Clin Invest"},{"key":"R15-22-20210227","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000063449","article-title":"Epidemiology of osteoporotic fractures.","volume":"54","author":"Dennison","year":"2000","journal-title":"Horm Res"},{"key":"R16-22-20210227","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy.","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"R18-22-20210227","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJM199809103391104","article-title":"Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group.","volume":"339","author":"Cummings","year":"1998","journal-title":"N Engl J Med"},{"key":"R19-22-20210227","first-page":"21","article-title":"Osteoporotic fractures: mortality and quality of life.","volume":"49","author":"Caliri","year":"2007","journal-title":"Panminerva Med"},{"key":"R20-22-20210227","first-page":"1551","article-title":"The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study.","volume":"34","author":"Salaffi","year":"2007","journal-title":"J Rheumatol"},{"key":"R21-22-20210227","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s00198-004-1702-6","article-title":"Epidemiology of osteoporotic fractures.","volume":"16","author":"Johnell","year":"2005","journal-title":"Osteoporos Int"},{"key":"R22-22-20210227","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0889-857X(05)70197-6","article-title":"The nonskeletal consequences of osteoporotic fractures. Psychologic and social outcomes.","volume":"27","author":"Gold","year":"2001","journal-title":"Rheum Dis Clin North Am"},{"key":"R23-22-20210227","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/01.gme.0000222475.93345.b3","article-title":"Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society.","volume":"13","year":"2006","journal-title":"Menopause"},{"key":"R24-22-20210227","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7326\/0003-4819-148-3-200802050-00198","article-title":"Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis.","volume":"148","author":"MacLean","year":"2008","journal-title":"Ann Intern Med"},{"key":"R25-22-20210227","first-page":"37","article-title":"Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women.","volume":"81","author":"Raisz","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"R26-22-20210227","first-page":"507","article-title":"Postmenopausal osteoporosis and hormone replacement therapy.","volume":"95","author":"Gambacciani","year":"2004","journal-title":"Minerva Med"},{"key":"R27-22-20210227","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1001\/jama.286.22.2815","article-title":"Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment.","volume":"286","author":"Siris","year":"2001","journal-title":"JAMA"},{"key":"R28-22-20210227","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jama.1996.03540170033029","article-title":"Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen\/Progestin Interventions (PEPI) trial.","volume":"276","year":"1996","journal-title":"JAMA"},{"key":"R29-22-20210227","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0002-9378(92)91653-R","article-title":"Low-dosage micronized 17-estradiol prevents bone loss in postmenopausal women.","volume":"166","author":"Ettinger","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"R30-22-20210227","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1210\/er.2001-5002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women.","volume":"23","author":"Wells","year":"2002","journal-title":"Endocr Rev"},{"key":"R32-22-20210227","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1210\/jc.2002-020727","article-title":"Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers.","volume":"87","author":"Gallagher","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R33-22-20210227","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","article-title":"Changes in bone density and turnover after alendronate or estrogen withdrawal.","volume":"11","author":"Wasnich","year":"2004","journal-title":"Menopause"},{"key":"R34-22-20210227","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.bone.2003.12.021","article-title":"Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study.","volume":"34","author":"Bagger","year":"2004","journal-title":"Bone"},{"key":"R35-22-20210227","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s00198-004-1773-4","article-title":"Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women.","volume":"16","author":"Lindsay","year":"2005","journal-title":"Osteoporos Int"},{"key":"R36-22-20210227","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.287.20.2668","article-title":"Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women.","volume":"287","author":"Lindsay","year":"2002","journal-title":"JAMA"},{"key":"R37-22-20210227","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1001\/jama.285.22.2891","article-title":"Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials.","volume":"285","author":"Torgerson","year":"2001","journal-title":"JAMA"},{"key":"R38-22-20210227","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"R39-22-20210227","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"R40-22-20210227","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"key":"R41-22-20210227","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1359\/jbmr.060312","article-title":"Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women's Health Initiative randomized trial.","volume":"21","author":"Jackson","year":"2006","journal-title":"J Bone Miner Res"},{"key":"R42-22-20210227","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.clinthera.2006.06.013","article-title":"Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg\/2.5 mg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials.","volume":"28","author":"Rowan","year":"2006","journal-title":"Clin Ther"},{"key":"R44-22-20210227","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/01.AOG.0000158120.47542.18","article-title":"Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.","volume":"105","author":"Barnabei","year":"2005","journal-title":"Obstet Gynecol"},{"key":"R45-22-20210227","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jama.288.1.58","article-title":"Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen\/Progestin Replacement Study follow-up (HERS II).","volume":"288","author":"Hulley","year":"2002","journal-title":"JAMA"},{"key":"R46-22-20210227","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1001\/jama.295.14.1647","article-title":"Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.","volume":"295","author":"Stefanick","year":"2006","journal-title":"JAMA"},{"key":"R47-22-20210227","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the risk of coronary heart disease.","volume":"349","author":"Manson","year":"2003","journal-title":"N Engl J Med"},{"key":"R48-22-20210227","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJM199109123251102","article-title":"Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study.","volume":"325","author":"Stampfer","year":"1991","journal-title":"N Engl J Med"},{"key":"R49-22-20210227","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/jwh.2006.15.35","article-title":"Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation.","volume":"15","author":"Grodstein","year":"2006","journal-title":"J Womens Health (Larchmt)"},{"key":"R50-22-20210227","doi-asserted-by":"crossref","first-page":"933","DOI":"10.7326\/0003-4819-133-12-200012190-00008","article-title":"A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.","volume":"133","author":"Grodstein","year":"2000","journal-title":"Ann Intern Med"},{"key":"R51-22-20210227","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1525-1497.2006.00389.x","article-title":"Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis.","volume":"21","author":"Salpeter","year":"2006","journal-title":"J Gen Intern Med"},{"key":"R52-22-20210227","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1161\/CIRCULATIONAHA.105.594077","article-title":"Effects of conjugated equine estrogen on stroke in the Women's Health Initiative.","volume":"113","author":"Hendrix","year":"2006","journal-title":"Circulation"},{"key":"R53-22-20210227","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S0015-0282(03)01167-1","article-title":"Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results.","volume":"80","author":"Pickar","year":"2003","journal-title":"Fertil Steril"},{"key":"R54-22-20210227","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/gme.0b013e31817b076a","article-title":"Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society.","volume":"15","year":"2008","journal-title":"Menopause"},{"key":"R55-22-20210227","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0889-8529(02)00079-8","article-title":"Bisphosphonates.","volume":"32","author":"McClung","year":"2003","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R56-22-20210227","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00198-003-1571-4","article-title":"Alendronate in the prevention of osteoporosis: 7-year follow-up.","volume":"15","author":"Sambrook","year":"2004","journal-title":"Osteoporos Int"},{"key":"R57-22-20210227","doi-asserted-by":"crossref","first-page":"935","DOI":"10.7326\/0003-4819-131-12-199912210-00005","article-title":"Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial.","volume":"131","author":"Ravn","year":"1999","journal-title":"Ann Intern Med"},{"key":"R58-22-20210227","first-page":"1492","article-title":"Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group.","volume":"85","author":"Ravn","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R59-22-20210227","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1210\/jc.2003-031672","article-title":"Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study.","volume":"89","author":"McClung","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R60-22-20210227","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"R61-22-20210227","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/13697130500118126","article-title":"Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.","volume":"8","author":"Hooper","year":"2005","journal-title":"Climacteric"},{"key":"R62-22-20210227","first-page":"396","article-title":"Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.","volume":"83","author":"Mortensen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"R63-22-20210227","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.0301202","article-title":"Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.","volume":"19","author":"McClung","year":"2004","journal-title":"J Bone Miner Res"},{"key":"R64-22-20210227","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2796.2003.01174.x","article-title":"Oral weekly ibandronate prevents bone loss in postmenopausal women.","volume":"254","author":"Tanko","year":"2003","journal-title":"J Intern Med"},{"key":"R65-22-20210227","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/ard.62.10.969","article-title":"Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.","volume":"62","author":"Stakkestad","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R66-22-20210227","first-page":"77","article-title":"Differences between the bisphosphonates for the prevention and treatment of osteoporosis.","volume":"2","author":"Grey","year":"2006","journal-title":"Ther Clin Risk Manag"},{"key":"R67-22-20210227","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bone.2008.09.011","article-title":"Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.","volume":"44","author":"McClung","year":"2009","journal-title":"Bone"},{"key":"R68-22-20210227","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/AOG.0b013e3181bdce0a","article-title":"Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial.","volume":"114","author":"McClung","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R69-22-20210227","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2165\/00002018-200730090-00003","article-title":"Safety considerations with bisphosphonates for the treatment of osteoporosis.","volume":"30","author":"Strampel","year":"2007","journal-title":"Drug Saf"},{"key":"R70-22-20210227","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1345\/aph.1L555","article-title":"Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.","volume":"43","author":"Blumentals","year":"2009","journal-title":"Ann Pharmacother"},{"key":"R71-22-20210227","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/SMJ.0b013e31819ed0dd","article-title":"Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.","volume":"102","author":"Binkley","year":"2009","journal-title":"South Med J"},{"key":"R72-22-20210227","first-page":"54","article-title":"Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project.","volume":"61","author":"Dalle","year":"2009","journal-title":"Reumatismo"},{"key":"R73-22-20210227","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/BOR.0b013e32832ca433","article-title":"Osteoporosis treatments and adverse events.","volume":"21","author":"Solomon","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"R74-22-20210227","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.14219\/jada.archive.2008.0110","article-title":"Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs.","volume":"139","author":"Edwards","year":"2008","journal-title":"J Am Dent Assoc"},{"key":"R75-22-20210227","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"R76-22-20210227","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","article-title":"Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.","volume":"362","author":"Black","year":"2010","journal-title":"N Engl J Med"},{"key":"R77-22-20210227","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2165\/00002018-200932030-00004","article-title":"Bisphosphonates and atrial fibrillation: systematic review and meta-analysis.","volume":"32","author":"Loke","year":"2009","journal-title":"Drug Saf"},{"key":"R78-22-20210227","first-page":"437","article-title":"Recent advances in estrogen receptor modulators.","volume":"8","author":"Henke","year":"2005","journal-title":"Curr Opin Drug Discov Devel"},{"key":"R79-22-20210227","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.","volume":"337","author":"Delmas","year":"1997","journal-title":"N Engl J Med"},{"key":"R80-22-20210227","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1001\/archinte.160.22.3444","article-title":"Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.","volume":"160","author":"Johnston","year":"2000","journal-title":"Arch Intern Med"},{"key":"R81-22-20210227","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/01.GME.0000058772.59606.2A","article-title":"Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.","volume":"10","author":"Jolly","year":"2003","journal-title":"Menopause"},{"key":"R82-22-20210227","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1185\/030079908X273282","article-title":"Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.","volume":"24","author":"Burshell","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"R84-22-20210227","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1185\/030079905X61839","article-title":"Safety assessment of raloxifene over eight years in a clinical trial setting.","volume":"21","author":"Martino","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"R85-22-20210227","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"key":"R86-22-20210227","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1161\/CIRCULATIONAHA.108.817577","article-title":"Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for the Heart trial: results of subgroup analyses by age and other factors.","volume":"119","author":"Collins","year":"2009","journal-title":"Circulation"},{"key":"R87-22-20210227","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.ajog.2004.04.042","article-title":"Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.","volume":"191","author":"Aldrighi","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"R88-22-20210227","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1517\/14656566.3.6.681","article-title":"The search for the ideal SERM.","volume":"3","author":"Arun","year":"2002","journal-title":"Expert Opin Pharmacother"},{"key":"R89-22-20210227","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","article-title":"Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.","volume":"23","author":"Miller","year":"2008","journal-title":"J Bone Miner Res"},{"key":"R90-22-20210227","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.","volume":"23","author":"Silverman","year":"2008","journal-title":"J Bone Miner Res"},{"key":"R91-22-20210227","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1177\/1933719108325759","article-title":"A new approach to menopausal therapy: the tissue selective estrogen complex.","volume":"15","author":"Komm","year":"2008","journal-title":"Reprod Sci"},{"key":"R92-22-20210227","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1210\/en.2008-0817","article-title":"The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention.","volume":"149","author":"Kharode","year":"2008","journal-title":"Endocrinology"},{"key":"R93-22-20210227","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.fertnstert.2009.02.093","article-title":"Efficacy of tissue-selective estrogen complex of bazedoxifene\/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.","volume":"92","author":"Lindsay","year":"2009","journal-title":"Fertil Steril"},{"key":"R94-22-20210227","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/gme.0b013e3181a7df0d","article-title":"Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene\/conjugated estrogens: a randomized, controlled trial.","volume":"16","author":"Pinkerton","year":"2009","journal-title":"Menopause"},{"key":"R95-22-20210227","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.fertnstert.2009.03.113","article-title":"Evaluation of bazedoxifene\/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.","volume":"92","author":"Lobo","year":"2009","journal-title":"Fertil Steril"},{"key":"R96-22-20210227","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.fertnstert.2009.05.094","article-title":"Endometrial effects of a tissue selective estrogen complex containing bazedoxifene\/conjugated estrogens as a menopausal therapy.","volume":"92","author":"Pickar","year":"2009","journal-title":"Fertil Steril"},{"key":"R97-22-20210227","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.fertnstert.2009.05.093","article-title":"Bazedoxifene\/conjugated estrogens (BZA\/CE): incidence of uterine bleeding in postmenopausal women.","volume":"92","author":"Archer","year":"2009","journal-title":"Fertil Steril"},{"key":"R98-22-20210227","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.gme.0000188736.69617.4f","article-title":"Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.","volume":"13","author":"McClung","year":"2006","journal-title":"Menopause"},{"key":"R99-22-20210227","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMoa0808692","article-title":"Lasofoxifene in postmenopausal women with osteoporosis.","volume":"362","author":"Cummings","year":"2010","journal-title":"N Engl J Med"},{"key":"R100-22-20210227","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density.","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"R101-22-20210227","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis.","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"R102-22-20210227","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ando.2007.06.015","article-title":"Hormonal replacement therapy (HRT) in postmenopause: a reappraisal.","volume":"68","author":"Caufriez","year":"2007","journal-title":"Ann Endocrinol (Paris)"},{"key":"R103-22-20210227","first-page":"1","article-title":"Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society.","volume":"14","year":"2007","journal-title":"Menopause"}],"container-title":["Menopause"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00042192-201101000-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T11:30:34Z","timestamp":1740310234000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042192-201101000-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/gme.0b013e3181e324a6","relation":{},"ISSN":["1072-3714"],"issn-type":[{"value":"1072-3714","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}